X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (121) 121
Publication (13) 13
Newspaper Article (9) 9
Newsletter (7) 7
Book Review (5) 5
Book Chapter (4) 4
Magazine Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (101) 101
humans (99) 99
hepatitis c virus (86) 86
hepatitis c (71) 71
antiviral agents - therapeutic use (69) 69
hepatitis c, chronic - drug therapy (56) 56
protease inhibitors (56) 56
hepacivirus - drug effects (55) 55
ribavirin (54) 54
hepacivirus - genetics (49) 49
gastroenterology & hepatology (47) 47
interferon (45) 45
proteases (42) 42
antiviral agents (41) 41
biological response modifiers (41) 41
protease inhibitor (40) 40
genotype (38) 38
drug therapy, combination (37) 37
hepatitis (36) 36
ribavirin - therapeutic use (34) 34
telaprevir (34) 34
viral nonstructural proteins - antagonists & inhibitors (34) 34
treatment-naive patients (32) 32
drug therapy (30) 30
health aspects (30) 30
hepatitis c - drug therapy (30) 30
treatment outcome (30) 30
antiviral agents - pharmacology (29) 29
antiviral agents - adverse effects (26) 26
interferon-alpha - therapeutic use (25) 25
male (25) 25
virus diseases (25) 25
care and treatment (24) 24
female (24) 24
hepatitis c, chronic - virology (23) 23
oligopeptides - therapeutic use (23) 23
clinical trials (21) 21
plus ribavirin (21) 21
protease inhibitors - therapeutic use (21) 21
sustained virological response (21) 21
middle aged (20) 20
pharmacology & pharmacy (20) 20
resistance (20) 20
antiviral activity (19) 19
boceprevir (19) 19
viruses (19) 19
genotypes (18) 18
polyethylene glycols - therapeutic use (18) 18
therapy (18) 18
infectious diseases (17) 17
research (17) 17
antiviral agents - administration & dosage (15) 15
clinical trials as topic (15) 15
combination therapy (15) 15
digestive system diseases (15) 15
gastroenterology and hepatology (15) 15
genetic aspects (15) 15
hepacivirus - enzymology (15) 15
ns5a inhibitor (15) 15
peginterferon alpha-2a (15) 15
pegylated interferon (15) 15
adult (14) 14
antiviral agents - chemistry (14) 14
direct-acting antivirals (14) 14
genotype & phenotype (14) 14
hepatitis c - virology (14) 14
hepatology (14) 14
medicine (14) 14
polymerase inhibitor (14) 14
recombinant proteins - therapeutic use (14) 14
virology (14) 14
genotype 1 infection (13) 13
liver (13) 13
pharmaceutical industry (13) 13
virus-infection (13) 13
chronic hepatitis-c (12) 12
combination (12) 12
drug resistance, viral (12) 12
in-vitro (12) 12
infection (12) 12
infections (12) 12
proline - analogs & derivatives (12) 12
proteins (12) 12
review (12) 12
virus (12) 12
animals (11) 11
chronic hepatitis c (11) 11
dependent rna-polymerase (11) 11
drug resistance (11) 11
liver cirrhosis (11) 11
medical research (11) 11
medicine & public health (11) 11
microbiology (11) 11
multidisciplinary sciences (11) 11
peginterferon (11) 11
product development (11) 11
proline - therapeutic use (11) 11
proteinase inhibitors (11) 11
science (11) 11
serine proteinase inhibitors - therapeutic use (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastroenterology, ISSN 0016-5085, 2011, Volume 141, Issue 6, pp. 2047 - 2055
Background & Aims Therapeutic regimens are being developed for patients with hepatitis C virus (HCV) infection that do not include the combination of... 
Gastroenterology and Hepatology | Drug | Peginterferon-Free | Direct-Acting Antivirals | Clinical Trial | ANTIVIRAL AGENTS | VIROLOGICAL RESPONSE SVR | CHRONIC HEPATITIS-C | IN-VITRO | THERAPY | PEGINTERFERON ALPHA-2A | COMBINATION TREATMENT | RESISTANCE | GENOTYPE 1 INFECTION | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | Acrylates - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA Replicase - antagonists & inhibitors | RNA, Viral - blood | Thiazoles - therapeutic use | Oligopeptides - adverse effects | Thiazoles - adverse effects | Viral Load | Acrylates - adverse effects | Oligopeptides - therapeutic use | Protease Inhibitors - adverse effects | Female | Benzimidazoles - adverse effects | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Benzimidazoles - therapeutic use | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | RNA, Viral - analysis | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Ribavirin - adverse effects | Antiviral Agents - adverse effects | RNA, Viral - drug effects | Viral Nonstructural Proteins - antagonists & inhibitors | Complications and side effects | Antiviral agents | Care and treatment | Protease inhibitors | Proteases | Universities and colleges | Hepatitis C | Hepatitis C virus | Ribavirin | Anti-HIV agents
Journal Article
Antiviral Therapy, ISSN 1359-6535, 2013, Volume 18, Issue 8, pp. 1015 - 1019
Background: Faldaprevir (BI 201335) and deleobuvir (BI 207127) are direct-acting antiviral agents under development for the treatment of chronic HCV infection.... 
NS5B POLYMERASE | ALPHA-2A | INFECTIOUS DISEASES | EFFICACY | SAFETY | CHRONIC HEPATITIS-C | BI201335 | COMBINATION | PROTEASE INHIBITOR | TRIAL | VIROLOGY | PHARMACOLOGY & PHARMACY | INFECTION
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2012, Volume 57, Issue 1, pp. 39 - 46
Background & Aims BI 207127 is a potent non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor in vitro. Methods In this double-blind,... 
Gastroenterology and Hepatology | Hepatitis C | Direct-acting antiviral | NS5B polymerase inhibitor | Genotype-1 | PEGYLATED INTERFERON ALPHA-2A | PLUS RIBAVIRIN | C-VIRUS-RNA | VIROLOGICAL RESPONSE SVR | TELAPREVIR | SAFETY | PROTEASE INHIBITOR | RESISTANCE | HCV GENOTYPE-1 PATIENTS | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | Antiviral Agents - pharmacokinetics | Humans | Middle Aged | Drug Resistance, Viral | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - pharmacokinetics | Recombinant Proteins - adverse effects | Young Adult | Ribavirin - administration & dosage | Ribavirin - pharmacokinetics | Interferon-alpha - pharmacokinetics | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Polyethylene Glycols - pharmacokinetics | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Aged | Interferon-alpha - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Antiviral agents | Hotels and motels | Liquid chromatography | Chromatography | Ribavirin | Hepatitis | Protease inhibitors | Proteases | Electrocardiogram | Nucleosides | Electrocardiography | Interferon | Hepatitis C virus | Mass spectrometry
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 7, pp. 630 - 639
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 11/2014, Volume 289, Issue 48, pp. 33456 - 33468
Journal Article
Liver International, ISSN 1478-3223, 02/2015, Volume 35, Issue 2, pp. 417 - 421
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2016, Volume 11, Issue 12, p. e0168544
This study evaluated the interferon-free, oral combination of deleobuvir (non-nucleoside HCV NS5-RNA-polymerase inhibitor) and faldaprevir (HCV NS3/4A-protease... 
INFECTION | BI 207127 | INHIBITOR | MULTIDISCIPLINARY SCIENCES | Acrylates - therapeutic use | Prognosis | Follow-Up Studies | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Hepatitis C, Chronic - complications | Thiazoles - therapeutic use | Viral Load | Oligopeptides - therapeutic use | Young Adult | RNA, Viral - genetics | Adult | Female | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Liver Cirrhosis - drug therapy | Antiviral Agents - therapeutic use | Liver Cirrhosis - complications | Ribavirin - therapeutic use | Genotype | Hepatitis C, Chronic - drug therapy | Liver Cirrhosis - virology | Adolescent | Aged | Care and treatment | Dosage and administration | Genetic aspects | Research | Diagnosis | Biological response modifiers | Hepatitis C virus | Health aspects | Ribavirin | Liver | Impairment | Viruses | Infections | DNA-directed RNA polymerase | Confidence intervals | Hepatitis | Genotype & phenotype | Vomiting | Safety | Target detection | Genotypes | Effectiveness | Diarrhea | Nausea | RNA polymerase | Ribonucleic acid--RNA | Patients | Studies | Polymerase | Cirrhosis | Inhibitors | Interferon | Hepatitis C | Pharmaceuticals | Cirrosi hepàtica | Assaigs clínics | Liver diseases | Hepatic cirrhosis | Virus de l'hepatitis C | Clinical trials | Malalties del fetge | RNA | Ribonucleic acid
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2016, Volume 11, Issue 8, p. e0160668
Background & Aim The resistance profile of anti-hepatitis C virus (HCV) agents used in combination is important to guide optimal treatment regimens. We... 
PRECLINICAL CHARACTERIZATION | THERAPY | BI 207127 | VARIANTS | SOFOSBUVIR | MULTIDISCIPLINARY SCIENCES | INFECTION | RIBAVIRIN | INHIBITOR | HEPATITIS-C | BMS-791325 | Acrylates - therapeutic use | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Thiazoles - therapeutic use | Hepacivirus - metabolism | Oligopeptides - therapeutic use | Clinical Trials, Phase III as Topic | Protease Inhibitors - therapeutic use | Benzimidazoles - therapeutic use | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Carrier Proteins - antagonists & inhibitors | Viral Nonstructural Proteins - genetics | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Mutation - genetics | Polymorphism, Genetic - drug effects | Carrier Proteins - genetics | Carrier Proteins - metabolism | Drug Resistance, Viral - drug effects | Polymorphism, Genetic - genetics | Viral Nonstructural Proteins - metabolism | Hepatitis C, Chronic - genetics | Viral Nonstructural Proteins - antagonists & inhibitors | Clinical Trials, Phase I as Topic | Amino Acid Substitution | Clinical Trials, Phase II as Topic | Antiviral agents | Complications and side effects | Drug resistance in microorganisms | Proteases | Physiological aspects | Dosage and administration | Genetic aspects | Research | Hepatitis C | Drug therapy | Clinical trials | Amino acids | Viruses | Infections | Ribavirin | Disease resistance | Hepatitis | Genotype & phenotype | Consolidation | Protease | Gastroenterology | Genotypes | Alanine | RNA polymerase | Patients | RNA-directed RNA polymerase | Studies | Polymerase | Inhibitors | Acids | Interferon | Hepatitis C virus | Binding sites | Polymorphism | Pharmaceuticals
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 07/2013, Volume 23, Issue 14, pp. 4132 - 4140
Journal Article
15.